[Ac 225]RTX-2358 / Ratio Therap - LARVOL DELTA

The ATLAS Study: A First-in-Human Phase 1/2 Trial of [Ac-225]RTX-2358 in Patients with Relapsed or Refractory FAP Positive Soft Tissue Sarcoma. (ESMO 2026) - No abstract available

Clinical • First-in-human • P1/2 data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • FAP

ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Ratio Therapeutics, Inc. | N=30 ➔ 48

Enrollment change • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure (PRNewswire) - "Proceeds from the financing will fuel Ratio's next phase of growth. The company expects to use the funding to advance its ongoing ATLAS study evaluating its lead radiotherapeutic asset [Ac-225]RTX-2358 in advanced sarcomas, and to move its next-generation RLT candidate into the clinic."

Financing • Non Small Cell Lung Cancer • Sarcoma

Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Checkpoint inhibition • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FAP

The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma. (ASCO 2026) - P1 | "Recruitment of the first cohort was completed in December 2025. The ATLAS Study: NCT07156565"

Clinical • First-in-human • P1/2 data • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CAFs • FAP

Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358 (PRNewswire) - "Under the expanded agreement, PharmaLogic will increase manufacturing capacity for the clinical supply of Ratio's fibroblast activation protein-alpha (FAP)-targeted therapeutic, [Ac-225]RTX-2358, by expanding manufacturing to PharmaLogic's Idaho Falls therapeutics facility. The broadened collaboration will also include enhancements of production processes with the aim of providing larger scale multi-dose batch manufacturing. The partnership is designed to support ongoing and future clinical studies, including later-stage and potentially registrational trials evaluating [Ac-225]RTX-2358 in FAP-expressing tumors."

Licensing / partnership • Soft Tissue Sarcoma

The ATLAS Study: A First-in-Human Phase 1/2 Trial of [Ac-225]RTX-2358 in Patients with Relapsed or Refractory Soft Tissue Sarcoma (SNMMI 2026) - P1 | "Trials In Progress"

Clinical • First-in-human • P1/2 data • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CAFs • FAP

The ATLAS Study: A First-in-Human Phase 1/2 Trial of [Ac-225]RTX-2358 in Patients with Relapsed or Refractory Soft Tissue Sarcoma (SNMMI 2026) - P1 | "Trials In Progress"

Clinical • First-in-human • P1/2 data • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CAFs • FAP

Initial Clinical Experience with [177Lu]Lu-RTX-2358 Radiopharmaceutical Therapy Targeting Fibroblast Activation Protein: Biodistribution, Pharmacokinetics, and Dosimetry. (PubMed, J Nucl Med) - " [177Lu]Lu-RTX-2358 demonstrated a manageable safety profile in a series of patients who were heavily pretreated for their disease. Given a promising therapeutic index as a result of prolonged retention in tumors and clearance from normal organs, further clinical evaluation is warranted."

Journal • PK/PD data • Oncology • Sarcoma • Solid Tumor • FAP

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas (PRNewswire) - "The ATLAS trial is a Phase 1/2 open-label clinical trial...designed to assess the safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225]-RTX-2358, a highly selective, FAP targeted radiotherapeutic labeled with Actinium 225, in patients with relapsed or refractory soft tissue sarcomas that express FAP."

Trial status • Soft Tissue Sarcoma

ATLAS: Actinium Therapy for Late-stage Aggressive Sarcomas (clinicaltrials.gov) - P1 | N=26 | Recruiting | Sponsor: Ratio Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

A PH/2 STUDY OF THE RADIOPHARMACEUTICAL [AC-225]RTX-2358 IN THE TREATMENT OF RELAPSED / REFRACTORY (R/R) SOFT TISSUE SARCOMA (STS) THE ATLAS STUDY - ACTINIUM THERAPY FOR LATE-STAGE AGGRESSIVE SARCOMAS (CTOS 2025) - "N/A"

Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CAFs • FAP